AI Article Synopsis

  • The study examined how high-resolution matching of specific human leucocyte antigens (HLA-A, -B, and -DRB1) affects the success of hematopoietic stem cell transplantation (HSCT) from matched unrelated donors (MUDs) versus those with single allele mismatches (mmUDs).
  • In patients receiving mmUDs, rejection rates were notably higher (14%) compared to MUDs (4%), primarily due to HLA-C mismatches, while the incidence of acute graft versus host disease (GVHD) was significantly greater in the mismatched groups.
  • The findings indicated that HLA class I mismatch was linked to higher risks of acute GVHD and transplant-related mortality, whereas HLA class II mism

Article Abstract

We studied the importance of human leucocyte antigen (HLA)-A, -B and -DRB1 high-resolution matching on the outcome of haematopoietic stem cell transplantation (HSCT) with matched unrelated donors (MUDs) vs single allele-mismatched unrelated donors. Fifty consecutive HSCT patients receiving an HLA-A, -B or -DR allele-level-mismatched unrelated graft (mmUD) were compared with a matched cohort of 100 patients with an HLA-A, -B and -DR-MUD. Rejection occurred in seven patients (14%) in the mmUD group and in four patients (4%) in the MUD group (P = 0.04), but this was mainly an effect of HLA-C mismatch. The cumulative incidence of acute graft vs host disease (GVHD) grades II-IV were 61%, 26% and 33% in the class I mmUD, class II mmUD and MUD groups, respectively. In multivariate analysis, HLA class I mismatch was associated with an increased risk of acute GVHD grades II-IV (2.09, P = 0.007) and transplant-related mortality (TRM) (1.99, P = 0.06). The 5-year overall survival was 81% in patients with a class II allele-mismatched donor compared with 52% (P = 0.025) and 50% (P = 0.017) in patients with a class I mismatch and a MUD. In multivariate analysis, HLA class II allele mismatch was associated with improved survival (3.38, P = 0.019). Relapse-free survival were 53%, 37% and 42% in patients with a class II mmUD, class I mmUD and a MUD, respectively (not significant). An HLA-C or -DQ mismatch had no significant impact on survival, TRM and relapse. In conclusion, compared with MUD, HLA class I allele mmUD had an increased risk of acute GVHD and TRM.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1399-0039.2008.01148.xDOI Listing

Publication Analysis

Top Keywords

class mmud
16
unrelated donors
12
hla class
12
patients class
12
class
9
outcome haematopoietic
8
haematopoietic stem
8
stem cell
8
cell transplantation
8
patients
8

Similar Publications

Optimized GVHD Prevention in HLA-Mismatched Unrelated Allogeneic HCT Using a PTCY-Based Approach.

Eur J Haematol

December 2024

Hematopoietic Transplantation Unit, Hematology Department, Clinical Institute of Hematology and Oncology (ICMHO), Hospital Clínic de Barcelona, Barcelona, Spain.

Although post-transplant cyclophosphamide (PTCY)-based prophylaxis has become a widely adopted strategy for preventing graft-versus-host disease (GVHD) in 9 out of 10 HLA-mismatched unrelated donors (MMUDs), allogeneic hematopoietic cell transplants (allo-HCTs), data on the safety and efficacy of PTCY in this setting remain limited. This single-center study investigates the outcomes of 94 adults with hematological malignancies undergoing MMUD allo-HCT with PTCY and tacrolimus (Tac) (PTCY-Tac) between 2014 and 2023. The median age was 53 years, and 60.

View Article and Find Full Text PDF

Purpose: This study retrospectively investigated the association between the level of human leukocyte antigen (HLA) mismatches (MMs), direction of disparities and differences at particular HLA locus on clinical outcomes of hematopoietic stem cell transplantation (HSCT). Investigated outcomes were overall survival (OS) and disease-free survival (DFS), graft-versus-host disease (GvHD), relapse and non-relapse mortality (NRM).

Patients And Methods: Study cohort included 108 adult patients transplanted between 2011 and 2021 and their 9/10 mismatched unrelated donors (MMUD).

View Article and Find Full Text PDF

Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.

Biol Blood Marrow Transplant

June 2018

Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Hospital Clínic, Barcelona, Spain; August Pi i Sunyer Biomedical Research Institute-IDIBAPS, Barcelona, Spain; Josep Carreras Leukaemia Research Foundation, Hospital Clínic, Barcelona, Spain. Electronic address:

The optimal prophylaxis regimen for graft-versus-host disease (GVHD) in the setting of mismatched unrelated donor (MMUD) allogeneic hematopoietic stem cell transplantation (alloHSCT) is not defined. The use of high-dose post-transplant cyclophosphamide (PTCy) in haploidentical transplantation has proven feasible and effective in overcoming the negative impact of HLA disparity on survival. We hypothesized that PTCy could also be effective in the setting of MMUD transplantation.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined how high-resolution matching of specific human leucocyte antigens (HLA-A, -B, and -DRB1) affects the success of hematopoietic stem cell transplantation (HSCT) from matched unrelated donors (MUDs) versus those with single allele mismatches (mmUDs).
  • In patients receiving mmUDs, rejection rates were notably higher (14%) compared to MUDs (4%), primarily due to HLA-C mismatches, while the incidence of acute graft versus host disease (GVHD) was significantly greater in the mismatched groups.
  • The findings indicated that HLA class I mismatch was linked to higher risks of acute GVHD and transplant-related mortality, whereas HLA class II mism
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!